A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
NCT06887803
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
26
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelofibrosis (MF)
Interventions
DRUG:
Roginolisib
Sponsor
iOnctura